- Home
- XCUR vs CLGN Comparison
XCUR vs CLGN Comparison
Compare XCUR & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XCUR
- CLGN
- Stock Information
- Founded
- XCUR 2011
- CLGN 2004
- Country
- XCUR United States
- CLGN Israel
- Employees
- XCUR N/A
- CLGN N/A
- Industry
- XCUR Biotechnology: Pharmaceutical Preparations
- CLGN Industrial Specialties
- Sector
- XCUR Health Care
- CLGN Health Care
- Exchange
- XCUR Nasdaq
- CLGN Nasdaq
- Market Cap
- XCUR 32.4M
- CLGN 33.8M
- IPO Year
- XCUR N/A
- CLGN N/A
- Fundamental
- Price
- XCUR $3.88
- CLGN $2.62
- Analyst Decision
- XCUR
- CLGN Strong Buy
- Analyst Count
- XCUR 0
- CLGN 2
- Target Price
- XCUR N/A
- CLGN $11.50
- AVG Volume (30 Days)
- XCUR 27.1K
- CLGN 31.1K
- Earning Date
- XCUR 11-13-2025
- CLGN 08-20-2025
- Dividend Yield
- XCUR N/A
- CLGN N/A
- EPS Growth
- XCUR N/A
- CLGN N/A
- EPS
- XCUR N/A
- CLGN N/A
- Revenue
- XCUR N/A
- CLGN $2,402,000.00
- Revenue This Year
- XCUR N/A
- CLGN $1,617.28
- Revenue Next Year
- XCUR N/A
- CLGN $83.54
- P/E Ratio
- XCUR N/A
- CLGN N/A
- Revenue Growth
- XCUR N/A
- CLGN 248.62
- 52 Week Low
- XCUR $1.44
- CLGN $1.31
- 52 Week High
- XCUR $36.00
- CLGN $5.12
- Technical
- Relative Strength Index (RSI)
- XCUR 23.53
- CLGN 51.56
- Support Level
- XCUR $3.10
- CLGN $2.56
- Resistance Level
- XCUR $7.06
- CLGN $2.77
- Average True Range (ATR)
- XCUR 0.38
- CLGN 0.19
- MACD
- XCUR -0.15
- CLGN -0.02
- Stochastic Oscillator
- XCUR 25.06
- CLGN 40.68
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.